Stevanato Group (NYSE:STVN) Issues FY 2026 Earnings Guidance

Stevanato Group (NYSE:STVN) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.690-0.730 for the period, compared to the consensus EPS estimate of 0.700. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Stevanato Group Stock Performance

STVN traded up €0.20 on Friday, hitting €18.23. The company’s stock had a trading volume of 655,782 shares, compared to its average volume of 670,153. The company’s 50 day simple moving average is €15.16 and its 200-day simple moving average is €18.75. The firm has a market cap of $5.52 billion, a P/E ratio of 31.43, a price-to-earnings-growth ratio of 1.70 and a beta of 0.75. The company has a quick ratio of 1.26, a current ratio of 1.76 and a debt-to-equity ratio of 0.23. Stevanato Group has a 12 month low of €12.89 and a 12 month high of €28.00.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Friday, May 8th. The company reported €0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). The company had revenue of €273.57 million for the quarter. Stevanato Group had a return on equity of 10.44% and a net margin of 11.83%.The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.10 earnings per share. Analysts forecast that Stevanato Group will post 0.7 EPS for the current year.

Wall Street Analysts Forecast Growth

STVN has been the subject of several recent analyst reports. Wall Street Zen cut shares of Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Citigroup reduced their price objective on shares of Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Jefferies Financial Group set a $17.50 price objective on shares of Stevanato Group in a research note on Tuesday, February 10th. Morgan Stanley reduced their price objective on shares of Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, March 6th. Finally, KeyCorp reduced their price objective on shares of Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

Institutional Trading of Stevanato Group

Institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna Portfolio Strategies LLC raised its holdings in shares of Stevanato Group by 62.8% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 72,554 shares of the company’s stock valued at $1,460,000 after acquiring an additional 27,991 shares in the last quarter. Brooklyn Investment Group purchased a new stake in shares of Stevanato Group in the 4th quarter valued at about $961,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Stevanato Group in the 3rd quarter valued at about $737,000. Goldman Sachs Group Inc. purchased a new stake in shares of Stevanato Group in the 4th quarter valued at about $608,000. Finally, Graham Capital Management L.P. purchased a new stake in shares of Stevanato Group in the 4th quarter valued at about $351,000.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.